The pharmaceutical sector is active against the market trend. In terms of news, the outbound licensing of Chinese innovative drugs reached a historical high in 2025, and the enthusiasm continues into 2026. As of March 27, the total amount of outbound licensing transactions has exceeded USD 60 billion, and the global cooperation value of domestic innovative drugs continues to be realized. In addition, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has approved its GLP-1 oral medication for market launch.
Institutions pointed out that today's market performance is weak due to the influence of &#34;external negative factors + cautious observation before the holiday,&#34; with light trading and narrow fluctuations in the index. Looking ahead, market sentiment remains cautious. On one hand, the current market is still highly concerned about the situation in the Middle East; on the other hand, during the intensive disclosure period of financial reports, the market is more focused on performance realization. In the medium term, if external disturbances ease marginally and industrial catalysts continue to be realized, the Science and Technology Innovation 200 Index is expected to achieve a central upward trend.
As of April 2, 2026, 15:00, the components of the Science and Technology Innovation 200 Index (000699) showed mixed performance, with Huiyu Pharmaceutical leading with a 10.77% increase, Huate Gas rising 7.30%, and Xinyi Chang up 5.74%; Xinghuan Technology led the decline. The latest quote for the Science and Technology Innovation 200 ETF Penghua (588240) is 1.51 yuan.
The Science and Technology Innovation 200 ETF Penghua closely tracks the Science and Technology Innovation 200 Index, which selects 200 securities with smaller market capitalization and better liquidity from the Shanghai Stock Exchange's Science and Technology Innovation Board as samples. The Science and Technology Innovation 200 Index, along with the Science and Technology Innovation 50 Index and the Science and Technology Innovation 100 Index, constitutes the scale index series of the Science and Technology Innovation Board, reflecting the overall performance of securities of listed companies of different market capitalizations on the Science and Technology Innovation Board.
The Science and Technology Innovation 200 ETF Penghua (588240) possesses the characteristics of &#34;hard technology&#34; logic + &#34;small and micro-cap&#34; opportunities + &#34;20% price fluctuation limit,&#34; making it a &#34;vanguard&#34; in historical rebound markets. The Science and Technology Innovation 200 Index gathers potential dark horses in innovation, with a balanced and diverse industry distribution, where pharmaceuticals account for nearly 15%. As of March 27, 2026, the Science and Technology Innovation 200 Index has risen 162.69% since the &#34;9.24&#34; market, and 73.99% since 2025, both far exceeding mainstream small and micro-cap indices such as the CSI 1000, CSI 2000, Guozheng 2000, and Chuangye 200, and also leading the Bei Zheng 50.
Data shows that as of March 31, 2026, the top ten weighted stocks in the Science and Technology Innovation 200 Index (000699) are Changguang Huaxin, Tengjing Technology, Juguang Technology, Dekeli, Jingzhida, Youkede, Jieput, Jiayuan Technology, Juhe Materials, and Weice Technology, with the top ten weighted stocks accounting for a total of 16.73%.
The Science and Technology Innovation 200 ETF Penghua (588240) has off-exchange connections (A: 023926; C: 023927)

516930

159316

159615

The Penghua SSE Science and Technology Innovation Board 200 ETF is actively traded, with the pharmaceutical sector performing outstandingly against the market trend. In 2025, China's innovative drug BD overseas licensing reached a historic high, with a total transaction amount exceeding 60 billion USD. Eli Lilly's GLP-1 oral medication has been approved by the FDA. The market has shown weak performance due to external negative factors and cautious observation ahead of the holiday, resulting in light trading. Looking ahead, if external disturbances decrease, the SSE Science and Technology Innovation Board 200 ETF is expected to rise. The latest quote for the Penghua SSE Science and Technology Innovation Board 200 ETF is 1.51 yuan, featuring a "hard technology" logic and a "20% price fluctuation limit" elasticity, with a balanced industry distribution, and the pharmaceutical sector accounting for nearly 15%

腾讯新闻 - 财经

Minsheng Royal CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

Invesco Nasdaq Biotechnology ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE Science and Technology Innovation Board 200 ETF

Direxion S&P Biotech Bull 3X

VG Health

Ping An CSI Medicine and Medical Device Innovation ETF

Eli Lilly

iShares Biotechnology ETF

科创200

ChinaAMC CSI Biotechnology Theme ETF

Ark Genomic Revolution ETF

Guotai CSI Bio-medicine ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Direxion S&P Biotech Bear 3X

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Tianhong CNI BIOMEDICINE ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE STAR Biology and Medicine ETF

Defiance Daily Target 2X Long LLY ETF

iShares US Pharma

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

Invesco Biotechnology & Genome ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Health Care Select Sector SPDR

Yinhua CSI Innovative Drugs Industry ETF

SPDR S&P Biotech

The Science and Technology Innovation 200 ETF by Penghua is actively traded, with the pharmaceutical sector performing well against the market trend